Press Releases
February 16, 2021
jCyte Announces Expansion of its Executive Leadership Team with Appointments in Commercial, Clinical and Manufacturing Operations
February 8, 2021
jCyte Announces Promotion of Dr. Shannon Blalock to Chief Executive Officer
July 27, 2020
jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
June 30,2020
jCyte Inc. Announces Scientific Advisory Board with Distinguished Retinal Physicians
In the News
Opthalmology Times | Oct 5, 2020
Intravitreally injected hRPCs improve vision in retinitis pigmentosa cases
Financial Times | Sept 14, 2020
Cell therapy opens up new cure horizons
Retinal Physician | Sept 1, 2020
Trial data on gene therapy, proposed Medicare cuts, FDA clearance of an AI diagnostic for DR, and more.
Optical Journal | Aug 13, 2020
jCyte Inc. Announces Promising Results In Retinitis Pigmentosa
The Stem Cellar | July 29, 2020
Encouraging news for treatment targeting retinitis pigmentosa
Eyewire News | July 27, 2020
jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
Endpoints News | July 27, 2020
Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb
Review of Ophthalmology | July 9, 2020
Regenerative Medicine In Ophthalmology
UCI | June 4, 2020
UCI Startup Company jCyte Partners with Santen Pharmaceutical
Orange County Business Journal | May 27, 2020
Biotech jCyte Inks $252M Licensing Deal
Healio | May 14, 2020
Santen to commercialize jCyte’s jCell therapy outside US
The Stem Cellar | May 11, 2020
A Clear Vision for the Future
Global Genes | May 11, 2020
JCyte Licenses Ex-US Rights to Retinitis Pigmentosa Cell Therapy to Santen for $252 Million
Pharmaceutical Business Review | May 11, 2020
JCyte signs ex-US licensing deal with Santen for retinal disease therapy
The Pharma Letter | May 9, 2020
jCyte out-licenses rare vision disorder treatment for $252 million
Biocentury | May 8, 2020
jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access
Bioworld | May 8, 2020
Santen inks $252M license to Jcyte ocular cell therapy
Media Contact
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744